Skip to main content

Table 2 The mean absorbed dose per administered activity

From: Estimation of absorbed dose to the kidneys in patients after treatment with 177Lu-octreotate: comparison between methods based on planar scintigraphy

Patient number First treatment cycle D/A administered (Gy/GBq)
  Kidney size/mass/AP thickness (cm/kg/cm)    Treatment cycle   
   1 2 3 4 5
1 Right (5.5/0.129/27) 0.68 0.87 0.72 0.51 ND
Left NA NA NA NA ND
2 Right (6.8/0.168/17) 0.38 0.48 0.45 0.37 0.52
Left (5.7/0.194/17) 0.43 0.70 0.57 0.52 0.33
3 Right (6.6/0.190/19) 1.09 0.76 0.82 0.84 ND
Left (5.27/0.154/19) 0.91 0.68 0.76 0.86 ND
4 Right NA NA NA NA ND
Left (4.3/0.113/21) 0.86 0.77 0.84 0.95 ND
5 Right NP NP NP NP NP
Left (6.4/0.234/23) 0.74 0.57 0.76 ND ND
6 Right (5.4/0.135/23) 0.89 ND ND ND ND
Left (5.6/0.137/22) 0.56 ND ND ND ND
7 Right (6.6/0.190/24) 0.60 0.60 0.62 ND ND
Left (5.8/0.161/25) 0.78 0.79 0.69 ND ND
8 Right (5.5/0.123/22) 0.60 0.60 0.62 1.1 ND
Left (5.0/0.152/23) 0.78 0.79 0.69 0.74 ND
9 Right (5.4/0.135/16) 0.96 1.2 ND ND ND
Left (3.0/0.054/18) 1.7 2.4 ND ND ND
10 Right (5.9/0.138/18) 1.2 1.3 ND ND ND
Left (5.6/0.149/17) 0.91 1.2 ND ND ND
11 Right (5.4/0.157/20) 0.77 0.94 0.92 1.1 ND
Left (6.3/0.177/20) 0.69 0.73 0.94 0.87 ND
12 Right (6.3/0.137/16) 0.73 0.61 0.59 ND ND
Left (5.8/0.168/17) 0.74 0.68 0.78 ND ND
13 Right (5.1/0.131/19) 0.59 0.87 0.79 ND ND
Left (5.1/0.107/20) NA NA NA ND ND
14 Right (3.7/0.087/18) NA NA NA ND ND
Left (4.7/0.088/19) 0.94 1.0 0.97 ND ND
15 Right (5.7/0.159/19) 1.3 ND ND ND ND
Left (5.2/0.188/18) 1.3 ND ND ND ND
16 Right (6.5/0.215/25) 0.63 0.59 0.61 0.56 ND
Left (6.3/0.231/26) 0.52 0.52 0.47 0.51 ND
17 Right (5.6/0.187/23) 0.50 0.47 0.50 0.63 ND
Left (6.4/0.215/24) 0.49 0.52 0.50 0.52 ND
18 Right (5.3/0.132/17) 0.85 0.88 0.94 ND ND
Left (5.2/0.117/19) 1.0 1.1 1.0 ND ND
19 Right NA NA NA ND ND
Left (4.5/0.094/21) 1.2 0.97 1.3 ND ND
20 Right (5.6/0.184/23) 0.66 0.56 0.57 0.57 ND
Left (5.6/0.153/23) 0.77 0.67 0.68 0.61 ND
21 Right (5.9/0.091/16) 1.5 1.6 ND ND ND
Left (4.7/0.098/18) 1.3 1.3 ND ND ND
22 Right (5.6/0.162/23) 0.73 0.74 0.73 0.64 ND
Left (5.6/0.194/24) 0.74 0.72 0.66 0.60 ND
23 Right NA NA NA ND ND
Left (4.7/0.124/20) 0.70 0.83 0.84 ND ND
24 Right NA NA NA NA ND
Left (5.6/0.167/24) 0.86 0.74 0.80 0.73 ND
25 Right (5.9/0.186/24) 0.55 0.48 0.44 0.46 ND
Left (5.9/0.209/26) 0.52 0.47 0.40 0.46 ND
26 Right (7.0/0.189/32) 1.3 1.4 ND ND ND
Left (5.5/0.145/30) 1.5 1.3 ND ND ND
27 Right (5.6/0.156/23) 1.2 1.3 1.2 ND ND
Left (6.1/0.200/22) 0.68 1.2 1.3 ND ND
28 Right (4.4/0.111/18) 1.0 1.0 ND ND ND
Left (5.1/0.158/19) 1.1 1.0 ND ND ND
29 Right NA NA NA NA ND
Left (5.6/0.181/21) 0.59 0.67 0.65 0.81 ND
30 Right (6.1/0.192/21) 0.51 0.48 0.43 ND ND
Left NA NA NA ND ND
31 Right NA NA ND ND ND
Left (4.9/0.118/18) 0.58 0.49 ND ND ND
32 Right (6.2/0.155/24) 0.95 NA ND ND ND
Left (6.4/0.168/24) 0.72 0.75 ND ND ND
33 Right (5.3/0.116/23) 1.0 ND ND ND ND
Left (5.3/0.161/22) 0.65 ND ND ND ND
  1. NP, not present; NA, not analyzable; ND, not done. The mean absorbed dose per administered activity (Gy/GBq) to the right and left kidneys for each patient given for each treatment cycle (1 to 5 per patient). Patient no. 5 had only one kidney. For patients no. 1, 4, 13, 14, 19, 23, 24, 29, 30, 31, and 32, it was not possible to determine the absorbed dose to one of the kidneys for one or several treatment cycles (see text).